[HTML][HTML] Primary, adaptive, and acquired resistance to cancer immunotherapy
P Sharma, S Hu-Lieskovan, JA Wargo, A Ribas - Cell, 2017 - cell.com
Cancer immunotherapy can induce long lasting responses in patients with metastatic
cancers of a wide range of histologies. Broadening the clinical applicability of these …
cancers of a wide range of histologies. Broadening the clinical applicability of these …
Targeting the cancer epigenome for therapy
Next-generation sequencing has revealed that more than 50% of human cancers harbour
mutations in enzymes that are involved in chromatin organization. Tumour cells not only are …
mutations in enzymes that are involved in chromatin organization. Tumour cells not only are …
Mechanisms of resistance to PD-1 and PD-L1 blockade
TS Nowicki, S Hu-Lieskovan, A Ribas - The Cancer Journal, 2018 - journals.lww.com
Cancer immunotherapy utilizing blockade of the PD-1/PD-L1 checkpoint has revolutionized
the treatment of a wide variety of malignancies, leading to durable therapeutic responses not …
the treatment of a wide variety of malignancies, leading to durable therapeutic responses not …
[HTML][HTML] Mechanisms regulating T-cell infiltration and activity in solid tumors
T-lymphocytes play a critical role in cancer immunity as evidenced by their presence in
resected tumor samples derived from long-surviving patients, and impressive clinical …
resected tumor samples derived from long-surviving patients, and impressive clinical …
A dual‐bioresponsive drug‐delivery depot for combination of epigenetic modulation and immune checkpoint blockade
Patients with advanced melanoma that is of low tumor‐associated antigen (TAA) expression
often respond poorly to PD‐1/PD‐L1 blockade therapy. Epigenetic modulators, such as …
often respond poorly to PD‐1/PD‐L1 blockade therapy. Epigenetic modulators, such as …
[HTML][HTML] Targeting DNA methylation and EZH2 activity to overcome melanoma resistance to immunotherapy
Methylation of DNA at CpG sites is the most common and stable of epigenetic changes in
cancer. Hypermethylation acts to limit immune checkpoint blockade immunotherapy by …
cancer. Hypermethylation acts to limit immune checkpoint blockade immunotherapy by …
[HTML][HTML] An update of epigenetic drugs for the treatment of cancers and brain diseases: a comprehensive review
Z Sahafnejad, S Ramazi, A Allahverdi - Genes, 2023 - mdpi.com
Epigenetics has long been recognized as a significant field in biology and is defined as the
investigation of any alteration in gene expression patterns that is not attributed to changes in …
investigation of any alteration in gene expression patterns that is not attributed to changes in …
Epigenetics in human disease and prospects for epigenetic therapy
Epigenetic mechanisms, which involve DNA and histone modifications, result in the
heritable silencing of genes without a change in their coding sequence. The study of human …
heritable silencing of genes without a change in their coding sequence. The study of human …
The power and the promise of DNA methylation markers
PW Laird - Nature Reviews Cancer, 2003 - nature.com
The past few years have seen an explosion of interest in the epigenetics of cancer. This has
been a consequence of both the exciting coalescence of the chromatin and DNA …
been a consequence of both the exciting coalescence of the chromatin and DNA …
[HTML][HTML] Targeting CDK9 reactivates epigenetically silenced genes in cancer
Summary Cyclin-dependent kinase 9 (CDK9) promotes transcriptional elongation through
RNAPII pause release. We now report that CDK9 is also essential for maintaining gene …
RNAPII pause release. We now report that CDK9 is also essential for maintaining gene …